Efficacy and Safety of Adalimumab 40 mg Weekly Dosingin Patients with Resistant Psoriasis
Meltem Turkmen & Sinan Dogan · Asian Journal of Research in Dermatological Science · 2021
Background: The recently updated dosing recommendation for adalimumab for psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may benefit from an increase in dosing frequency to 40 mg every week (EW). Objectives: This study...
Open access
Research Article